journal article·2020-03-09

Comparison of Regenerative Effects of Transplanting Three-Dimensional Longitudinal Scaffold Loaded-Human Mesenchymal Stem Cells and Human Neural Stem Cells on Spinal Cord Completely Transected Rats

Yunlong Zou, Yannan Zhao, Zhifeng Xiao, Bing Chen, Dezun Ma, He Shen, Rui Gu, Jianwu Dai

Publisher page

Abstract

Stem cell-based therapy has been considered as a potential treatment to restore spinal cord injury (SCI) through reconstructing neural networks and providing a favorable microenvironment for neuronal survival, differentiation, and axonal outgrowth. Biomaterial scaffolds can promote cell attachment and survival, neuronal differentiation, and axonal outgrowth; therefore, they were used to combine with stem cells for implantation in SCI treatment. In addition, a longitudinal scaffold can guide regenerated axons with orientated growth and axial extension. Both human umbilical cord-derived mesenchymal stem cells (hMSCs) and human fetal spinal cord-derived neural stem cells (hNSCs) have been applied in clinical trials worldwide. To our knowledge, a parallel comparison of the therapeutic effects of hMSC and hNSC implantations has not been conducted. Hence, in this study, we grafted hMSCs or hNSCs seeded on longitudinal collagen sponge scaffolds into rats with completely transected SCI to examine differences in SCI repair. Both hMSCs and hNSCs had equivalent effects on reducing glial scar formation around the lesion gap. More neuronal class III β-tubulin-positive neurons and neurofilament-positive nerve fibers were found in the lesion cavity after hNSC implantation. In addition, hNSCs had better capabilities to improve motor function, attenuate inflammation, and promote cell survival than hMSCs. These encouraging results provide a clinical basis for future stem cell-based SCI therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammatory Bowel Disease · Microscopic Colitis · Celiac Disease Research and Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

China−Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun 130033, China

State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, 3 Nanyitiao, Zhongguancun, Beijing 100101, China

Key Laboratory for Nano-Bio Interface Research, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China

Funding

the Program of Finance Jilin Province Department of Finance · the National Key Research and Development Program of China · the National Natural Science Foundation of China · the Strategic Priority Research Program of the Chinese Academy of Sciences

References (46)

Show source-provided references
1. 10.1038/s41591-019-0475-610.1038/s41591-019-0475-6 ↗
2. 10.1038/cr.2012.17110.1038/cr.2012.171 ↗
3. 10.3390/ijms1704053010.3390/ijms17040530 ↗
4. 10.1016/j.biomaterials.2013.02.00210.1016/j.biomaterials.2013.02.002 ↗
5. 10.3171/FOC.2008.25.11.E210.3171/FOC.2008.25.11.E2 ↗
6. 10.1038/nn.454110.1038/nn.4541 ↗
7. 10.1016/j.pmatsci.2019.02.00210.1016/j.pmatsci.2019.02.002 ↗
8. 10.1016/j.semcdb.2019.02.00210.1016/j.semcdb.2019.02.002 ↗
9. Lu L. L. · Haematologica · 2006 · 91 · 1017
10. 10.1007/s11427-016-5080-z10.1007/s11427-016-5080-z ↗
11. 10.1532/ijh97.a1040410.1532/ijh97.a10404 ↗
12. 10.1007/s12035-019-1570-x10.1007/s12035-019-1570-x ↗
13. 10.3389/fbioe.2017.0003210.3389/fbioe.2017.00032 ↗
14. 10.3390/ijms2011269810.3390/ijms20112698 ↗
15. 10.1073/pnas.161634011410.1073/pnas.1616340114 ↗
16. 10.1073/pnas.05267889910.1073/pnas.052678899 ↗
17. 10.1002/adfm.20160152110.1002/adfm.201601521 ↗
18. 10.1016/j.biomaterials.2013.03.06210.1016/j.biomaterials.2013.03.062 ↗
19. 10.1002/adhm.20160127910.1002/adhm.201601279 ↗
20. 10.1016/j.stemcr.2015.06.00410.1016/j.stemcr.2015.06.004 ↗
21. 10.2217/rme.11.12110.2217/rme.11.121 ↗
22. 10.1016/j.biomaterials.2019.01.01210.1016/j.biomaterials.2019.01.012 ↗
23. 10.1016/j.actbio.2017.01.00910.1016/j.actbio.2017.01.009 ↗
24. 10.1038/s41591-018-0296-z10.1038/s41591-018-0296-z ↗
25. 10.3727/096368911X56618110.3727/096368911X566181 ↗
26. 10.1039/c7bm00974g10.1039/c7bm00974g ↗
27. 10.1016/j.biomaterials.2014.11.03110.1016/j.biomaterials.2014.11.031 ↗
28. 10.1007/s11427-017-9049-y10.1007/s11427-017-9049-y ↗
29. 10.1021/acsami.5b0387910.1021/acsami.5b03879 ↗
30. 10.1177/096368971984452510.1177/0963689719844525 ↗
31. 10.1016/0168-5597(89)90038-510.1016/0168-5597(89)90038-5 ↗
32. 10.3171/jns.1977.47.4.057710.3171/jns.1977.47.4.0577 ↗
33. 10.1006/exnr.1996.009810.1006/exnr.1996.0098 ↗
34. 10.1089/neu.2018.633210.1089/neu.2018.6332 ↗
35. 10.1007/s00441-012-1375-y10.1007/s00441-012-1375-y ↗
36. 10.1039/c4bm00106k10.1039/c4bm00106k ↗
37. 10.1089/ten.TEA.2009.041410.1089/ten.TEA.2009.0414 ↗
38. 10.1186/s13287-016-0295-210.1186/s13287-016-0295-2 ↗
39. 10.1038/nm.450210.1038/nm.4502 ↗
40. 10.4252/wjsc.v6.i2.12010.4252/wjsc.v6.i2.120 ↗
41. 10.1097/BRS.0b013e31819403ce10.1097/BRS.0b013e31819403ce ↗
42. 10.1124/jpet.105.09718810.1124/jpet.105.097188 ↗
43. 10.1089/08977150175045185710.1089/089771501750451857 ↗
44. 10.1016/j.expneurol.2019.11298010.1016/j.expneurol.2019.112980 ↗
45. 10.1016/j.biomaterials.2015.11.05910.1016/j.biomaterials.2015.11.059 ↗
46. 10.1016/j.bbrc.2013.12.14210.1016/j.bbrc.2013.12.142 ↗